Amman Bradford K.
Known title: Principal Accounting OfficerCIK: 0001425339
Associated companies
Transaction History
| VVOS | ▲ Buy | Grant | 250,000 | $103K | 7/31/2026 | View on chart |
| VVOS | ▲ Buy | Grant | 250,000 | $103K | 7/31/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
VVOS Announces $3.6M Annual Cost‑Reduction Plan
Vivos Therapeutics disclosed a restructuring plan that aims to cut annual costs by $3.6 million beginning in the fourth quarter of 2026. The company also reported progress on material cost reductions and initiatives to grow revenue. These actions are intended to improve financial efficiency while supporting ongoing growth efforts.
VVOS Announces $3.6M Annual Cost‑Reduction Plan. Vivos Therapeutics disclosed a restructuring plan that aims to cut annual costs by $3.6 million beginning in the fourth quarter of 2026. The company also reported progress on material cost reductions and initiatives to grow revenue. These actions are intended to improve financial efficiency while supporting ongoing growth efforts.